Nasdaq · CIK 0001469443
RKDA Arcadia Biosciences, Inc.
Insider trading from SEC Form 4. Last filing 29 d ago. Close $0.26 on Oct 9, 2026, 0% from the 52-week low and -95% from the high.
Arcadia Biosciences, Inc. (RKDA) has 8 SEC Form 4 filings on file from 6 insiders, the latest filed on Sep 14, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
2 open-market trades have been scored at RKDA. The newest: Thomas J. Schaefer (Chief Executive Officer) bought $1,743 of stock on Feb 3, 2025, filed Feb 5, 2025, scored 39 (weak). 2 insiders bought within 14 days of each other around Feb 3, 2025.
RKDA closed at $0.26 on Oct 9, 2026, 0% above its 52-week low and 95% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Arcadia Biosciences, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 39Weak | Thomas J. Schaefer Chief Executive Officer buy | $1,743 700 shares | +33% | - | |
| 36Weak | Mark Kawakami Chief Financial Officer buy | $1,743 700 shares | +35% | - |
Transactions
Every row filed, 8 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | Lilian Shackelford Murray director | AGrant or award Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 23,287 | 29 d ago |
| Sep 10, 2026 | Gregory D Waller director | AGrant or award Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 23,338 | 29 d ago |
| Sep 10, 2026 | Kevin Comcowich director | AGrant or award Stock Option (Right to Buy)derivative | +23,000 | $0.00 | $0 | 54,042 | 29 d ago |
| Sep 10, 2026 | Amy Yoder director | AGrant or award Stock Option (Right to Buy)derivative | +10,000 | $0.00 | $0 | 23,442 | 29 d ago |
| May 9, 2025 | Thomas J. Schaefer Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +12,500 | $0.00 | $0 | 37,975 | May 12, 2025 |
| May 9, 2025 | Mark Kawakami Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +12,500 | $0.00 | $0 | 33,987 | May 12, 2025 |
| Feb 3, 2025 | Thomas J. Schaefer Chief Executive Officer | POpen-market purchase Common Stock | +700 | $2.49 | $1,743 | 2,819 | Feb 5, 2025 |
| Feb 3, 2025 | Mark Kawakami Chief Financial Officer | POpen-market purchase Common Stock | +700 | $2.49 | $1,743 | 2,681 | Feb 5, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Kevin Comcowichdirector
- Mark KawakamiChief Financial Officer
- Lilian Shackelford Murraydirector
- Thomas J. SchaeferChief Executive Officer
- Gregory D Wallerdirector
- Amy Yoderdirector
Questions about RKDA
Answered from the filings on this page, as of the latest one.
Are insiders buying RKDA?
No. In the last 90 days no insider at Arcadia Biosciences, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade RKDA on the open market?
Thomas J. Schaefer (Chief Executive Officer) bought $1,743 of RKDA on Feb 3, 2025 and filed the Form 4 on Feb 5, 2025. InsiderTell scored 39 (weak), with 2 insiders on the same side within 14 days.
How many insiders file Form 4 at Arcadia Biosciences, Inc.?
6 people have filed a Form 4 at Arcadia Biosciences, Inc., among them Kevin Comcowich (director), Mark Kawakami (Chief Financial Officer), Lilian Shackelford Murray (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.